XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Investments (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Dec. 31, 2022
Aug. 14, 2024
Mar. 14, 2024
Long-Term Investments [Line Items]          
Percentage of common stock shares 51.00%        
Aggregate amount     $ 2,688,578    
Prepayment amount     $ 1,895,556    
Converted shares     994,450    
Common stock, shares authorized [1] 100,000,000 100,000,000      
Ordinary shares issued 12,711,345 [1] 7,940,298 [1]   46,072 1,610,700
Ordinary shares outstanding [1] 12,711,345 7,940,298      
Joint venture $ 150,000        
BioFirst Corporation [Member]          
Long-Term Investments [Line Items]          
Percentage of common stock shares 18.68% 18.68%      
Prepayment amount $ 1,124,842        
Ordinary shares issued 3,049        
Ordinary shares outstanding 3,049        
Rgene Corporation [Member]          
Long-Term Investments [Line Items]          
Percentage of common stock shares 26.65% 26.65%      
BioLite Japan K.K. [Member]          
Long-Term Investments [Line Items]          
Percentage of common stock shares 49.00%        
Common stock, shares authorized 10,000        
Ordinary shares issued 1,555        
Joint venture $ 150,000        
BioLite JP [Member]          
Long-Term Investments [Line Items]          
Ordinary shares issued 1,494        
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.